Parliament Website

National Institute For Health And Clinical Excellence Ruling On Azacitidine

EDM number 1208 in 2009-10, proposed by John Leech on 30/03/2010.
Categorised under the topic of Diseases.

That this House notes that patients with myelodysplastic syndromes (MDS) suffer from chronic and severe fatigue and are at risk of progressing to a more aggressive form of leukaemia (acute myeloid leukaemia); observes that the drug azacitidine is the first and only licensed drug available specifically to treat MDS and has the ability both to slow the progress of the disease and immeasurably improve patients' quality of life; is disappointed at the recent National Institute for Health and Clinical Excellence (NICE) recommendation that azacitidine is not sufficiently cost-effective; recognises that as few as 700 patients would require the drug each year, which translates to a diminutive portion of the NHS budget; and calls on NICE to reconsider its recommendation on use of the drug which is already widely available in other Western European and North American countries.

This motion has been signed by a total of 15 MPs.

MPDateConstituencyPartyType
John Leech30/03/2010Manchester, WithingtonLiberal DemocratProposed
Peter Bottomley30/03/2010Worthing WestConservativeSeconded
Nigel Evans30/03/2010Ribble ValleyConservativeSeconded
Alan Meale30/03/2010MansfieldLabourSeconded
Bob Russell30/03/2010ColchesterLiberal DemocratSeconded
Bob Spink30/03/2010Castle PointIndependentSeconded
William McCrea06/04/2010South AntrimDUPSigned
Jeremy Corbyn06/04/2010Islington NorthLabourSigned
Andrew Pelling06/04/2010Croydon CentralIndependentSigned
Kelvin Hopkins07/04/2010Luton NorthLabourSigned
Albert Owen07/04/2010Ynys MLabourSigned
John Cummings07/04/2010EasingtonLabourSigned
Andrew Dismore07/04/2010HendonLabourSigned
Mark Durkan07/04/2010FoyleSocial Democratic and Labour PartySigned
Mark Hunter07/04/2010CheadleLiberal DemocratSigned

Download raw data as csv or xml.